Forget Short-Term Pain: Buy GlaxoSmithKline plc & Vodafone Group plc For Long-Term Gain!

Royston Wild takes a look at the long-term growth prospects of GlaxoSmithKline plc (LON: GSK) and Vodafone Group plc (LON: VOD).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Medicines giant GlaxoSmithKline (LSE: GSK) and telecoms titan Vodafone (LSE: VOD) have both had to endure their fair share of revenues problems in recent years.

For GlaxoSmithKline, the growing presence of generic competitors in its product suite has been a persistent drag on earnings. Meanwhile Vodafone has been smacked by rising competition and challenging economic conditions in its European heartland.

But could the tide be about to turn for both companies?

Drugs darling

Well, GlaxoSmithKline isn’t expected to put the problem of patent expirations behind it just yet. For example, sales of its critical Avodart prostate treatment slumped 42% between October and December to £110m. The decline was due to a loss of exclusivity in the US at the start of the period.

And tanking sales of the Seretide/Advair asthma treatment — a drug that accounts for two-thirds of revenues at GlaxoSmithKline’s Respiratory arm — underlines the scale of these competitive pressures. Global sales of £3.7bn last year represented a 30% decline from their peak in 2013.

Still, I believe GlaxoSmithKline is in great shape to put these travails behind it, even if it has a long road ahead of it. The company expects to make 20 new regulatory submissions by the close of the decade and another 20 in the following five-year period. And the Brentford firm believes that “80% of the medicines and vaccines… have the potential to be ‘first-in-class’.”

There’s no guarantee that these products will ever see the light of day of course, such is the unpredictable nature of drugs development.

But with GlaxoSmithKline doubling-down on its R&D investment in recent times, not to mention boosting its organic pipeline with shrewd acquisitions in hot growth areas, I believe the firm should make good on its development programmes.

Ring up roaring returns

Mobile operator Vodafone has also experienced persistent top-line troubles thanks to challenging conditions on the continent.

The business saw group organic service revenues slide 1.6% in the year to March 2015 as enduring weakness in Europe dragged the top line lower — sales on the continent fell a colossal 4.7% during the period.

But the fruits of Vodafone’s Project Spring organic investment programme in its data and voice coverage is helping to propel European turnover higher again. On top of this, shrewd M&A activity in the multi-services market — like the firm’s decision last month to merge its Dutch operations with those of Liberty Global — is also transforming the top line.

These actions caused continental turnover to slip by a more modest 1.3% between last April and September, and organic service revenues fell by just 0.6% in the most recent quarter.

It appears to be a matter of time before Vodafone’s sales in Europe — a territory responsible for two-thirds of group revenues — finally flip into the black. And with sales in Asia, the Middle East and Africa also taking off, I reckon Vodafone is on course to deliver stunning returns in the years ahead.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

Just released: our top 3 small-cap stocks to consider buying in October [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »